Ocular Therapeutix (OCUL) EBITDA (2013 - 2026)

Ocular Therapeutix's EBITDA history runs 14 years deep, the most recent figure standing at -$93.3 million for Q1 2026.

• On a quarterly basis, EBITDA fell 46.03% year-over-year to -$93.3 million in Q1 2026; TTM through Mar 2026 was -$299.4 million, a 46.73% decrease from a year earlier, with the FY2025 full-year figure at -$270.0 million, down 57.19% from the prior year.
• EBITDA declined to -$93.3 million in Q1 2026 per OCUL's latest filing, from -$69.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$17.8 million in Q1 2022 and bottomed at -$93.3 million in Q1 2026.
• The 5-year median for EBITDA is -$31.6 million (2024), against an average of -$41.0 million.
• Across the five-year window, EBITDA rose 11.84% in 2022 and slumped 152.25% in 2024, its largest moves.
• Year by year, EBITDA stood at -$19.4 million in 2022, then slipped by 3.56% to -$20.0 million in 2023, then slumped by 152.25% to -$50.6 million in 2024, then slumped by 37.93% to -$69.8 million in 2025, then sank by 33.8% to -$93.3 million in 2026.
• Per Business Quant, the three latest OCUL EBITDA figures stand at -$93.3 million (Q1 2026), -$69.8 million (Q4 2025), and -$68.7 million (Q3 2025).